News >

FDA, EMA Recommend Against Starting Olaratumab for Soft Tissue Sarcoma

Gina Columbus @ginacolumbusonc
Published: Thursday, Jan 24, 2019

The FDA has recommended that no new patients with advanced soft tissue sarcoma (STS) should be treated with the combination of olaratumab (Lartruvo) plus doxorubicin, following the negative results of the phase III ANNOUNCE trial.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication